Key facts
- This page summarizes Amit Sachdev's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 28 Feb 2022, 16:25.
Amit Sachdev - 24 Feb 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)
- Reporting relationship
- EVP, Chief Patient Officer
- Issuer ticker
- VRTX
- Reported as of
- 24 Feb 2022
- Net transaction value
- -$1,678,872
- SEC form
- 4
- Accepted by SEC
- 28 Feb 2022, 16:25:57 UTC
- Prior SEC filing
- 22 Feb 2022
- Next SEC filing
- 11 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sabrina Yohai, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Amit Sachdev filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 28 Feb 2022.
Change
- Previous filing in this sequence was filed on 22 Feb 2022.
- Current net transaction value: -$1,678,872.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRTX
transaction
Common Stock
Tax liability
- Transaction value
- $1,678,872
- Shares
- -7,368
- Change %
- -13%
- Price
- $227.86
- Shares after
- 48,210
- Date
- 24 Feb 2022
- Ownership
- Direct
VRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 882
- Date
- 24 Feb 2022
- Ownership
- 401(k)
VRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 15,573
- Date
- 24 Feb 2022
- Ownership
- Held in Trust
* marks a reported price that did not pass the local price check.